Eli Lilly and Company (LLY) Earnings Call Transcripts

Eli Lilly and Company's Latest Earnings Call - Q2 FY2026

In Q2 2026, Eli Lilly reported a remarkable 48% revenue growth year-over-year, driven by strong performance across key products, particularly in oncology, immunology, and neuroscience. The company raised its full-year revenue guidance to between $85 billion and $87 billion, reflecting robust underlying performance. Non-GAAP earnings per share reached $8.38, significantly up from $6.31 in Q2 2025, indicating strong operational efficiency and margin improvement.

Reported metrics

Guidance from management

Eli Lilly raised its full-year revenue guidance to between $85 billion and $87 billion, with non-GAAP EPS expected to be between $35.50 and $36.50, reflecting strong operational performance and confidence in future growth.

What management said

Thanks, Dan. We made excellent progress this quarter. We delivered strong business results, received regulatory approval for new indications, shared positive Phase III trial results added new medicines to our pipeline and expanded access to medicines for patients. While we're pleased with the progress this year so far, we're not satisfied. We remain focused on executing the 3 components of our strategy to deliver sus...

Thanks, Dave. As a reminder, we would like to address as many questions as possible, but consistent with the prior quarters, please limit yourself to a single one-part question. Paul, please provide the instructions for how to join the queue, and we're ready for the first caller.

What analysts pressed on

Analysts raised concerns about potential pricing pressures and the sustainability of net pricing strategies amidst increased competition from generics. There is also apprehension regarding the deceleration of revenue growth in the second half of the year compared to Q2, despite strong early indicators from new product launches and access programs.

Main topics on the call

• Revenue Growth Acceleration — Eli Lilly's revenue surged 48% compared to Q2 2025, with key products contributing nearly $6.8 billion in growth. Management noted, "We delivered robust revenue across all key products and major geographies," signaling s...
• Guidance Increase — The company raised its full-year revenue guidance by $3 billion at the low end and $2 billion at the high end, now expecting between $85 billion and $87 billion. This adjustment reflects confidence in ongoing product per...
• Pipeline Advancements — Lilly advanced its pipeline with several key regulatory approvals and positive trial results, including the FDA approval for lebrikizumab in atopic dermatitis. Management stated, "We achieved several key pipeline and reg...
• Market Share Leadership — Lilly strengthened its position in the incretin market, achieving a 55% share globally. Management emphasized, "We expect continued strong performance outside the U.S.," indicating confidence in international growth.

Read the full Eli Lilly and Company transcript (Q2 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 108 Eli Lilly and Company earnings call transcripts on record, spanning January 14, 2020 to August 5, 2026. Based on this history, Eli Lilly and Company reports quarterly. The most recent call on file is dated August 5, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

LLY

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

108

First call

January 14, 2020

Most recent

August 5, 2026

Reporting cadence

quarterly